One of the most discussed aspects of healthcare has to be how to balance cost, quality and access. This is especially true when it comes to the pharmaceutical industry, particularly with the rapid growth of and increased focus on highly effective, but highly expensive, specialty drugs. Discussions about these costs are no longer isolated to negotiations between pharmaceutical companies, PBMs and insurers; instead it appears that price and cost are on FDA's radar.
For example, the Oncologic Drugs Advisory Committee ("ODAC") hearing, earlier this month, was not only historic ...
Blog Editors
Recent Updates
- Breaking Down the Legal Challenges Surrounding State Licensure Restrictions for Telehealth Providers
- Interested in Opening a Medical Spa? Here’s What You Need to Know
- Podcast: Key Changes in Finalized Antitrust Merger Guidelines – Diagnosing Health Care
- FDA Releases Draft Guidance on New Dietary Ingredient Notification Master Files for Dietary Supplements
- Updated Requirements for Informed Consent: HHS Issues New Guidance on Sensitive Exams